



## MARTIN BOTT APPOINTED CFO OF BIOVERSYS

Basel, Switzerland. May 18, 2021, 9am CET

### Martin Bott Appointed Chief Financial Officer of BioVersys

BioVersys is strengthening its executive management team with the appointment of Martin Bott as Chief Financial Officer as of May 17, 2021. Martin will lead financial operations at BioVersys and support the company in its continued evolution as one of the leading, clinical stage biotech companies developing novel antibacterial therapies.

Martin has more than 30 years of financial management experience in the pharmaceutical industry. He has held various financial leadership roles at Eli Lilly and Company as Vice President Finance, including CFO of the Diabetes Business, CFO of the Global Manufacturing Organization, Leader of strategic review and subsequent IPO of Lilly's Animal Health business, Elanco Animal Health. Most recently, Martin served as Interim CEO of the industry-led AMR Action Fund, created to combat the growing public health threat of antimicrobial resistance.

Martin's primary mission is to secure a strong financial position for BioVersys to ensure the company will meet its development goals and deliver urgently needed novel antibiotics to patients in need.

Dr. Marc Gitzinger, CEO and founder of BioVersys: "We are delighted that Martin joins BioVersys during an exciting and important stage in our company's development. We are preparing to bring two of our lead programs into clinical Phase II and III development in our fight against antimicrobial resistance, which if left unchecked, has the potential to reach pandemic proportions. In this crucial phase, Martin brings significant financial leadership and strategic experience to the company."

"I am excited to join the talented team at BioVersys at this pivotal time," said Martin. "Antimicrobial resistance is a troubling and growing public health issue and I look forward to drawing from my financial, transaction and strategic experience to help drive the Company as it develops innovative and desperately needed medications for patients."

### About BioVersys

BioVersys AG is a privately-owned clinical stage Swiss pharmaceutical company focusing on research and development of small molecules acting on novel bacterial targets with applications in antimicrobial resistance (AMR) and targeted microbiome modulation. With the company's award-winning TRIC technology we can overcome resistance mechanisms, block virulence production and directly affect the pathogenesis of harmful bacteria, towards the identification of new treatment options in the antimicrobial and microbiome fields. By this means, BioVersys addresses the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. Our most advanced research and development programmes address nosocomial infections of *Acinetobacter*



*baumannii* (BV100, Phase 1), and tuberculosis (BVL-GSK098, Phase 1) in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille. BioVersys is located in the Technologiepark in the thriving biotech hub of Basel.

#### BioVersys contacts

**Alina Lundin**, Executive Assistant to CEO, Tel. +41 61 633 22 50; Mail: [info@bioversys.com](mailto:info@bioversys.com)

Website: [www.bioversys.com](http://www.bioversys.com).

